In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joanne Shorthouse

Latest From Joanne Shorthouse

Leading The Dawn Chorus

Spearheading discussions with NICE, bluebird bio’s UK general manager Nicola Redfern has been central to efforts to introduce fresh reimbursement models within the health technology assessment process and commercial framework. Success could change the way cell and gene therapies are assessed and affect the outlook for many patients living with rare diseases.

Market Access Gene Therapy

Bouncing Back From A Phase III Flop

The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.

Business Strategies Clinical Trials

Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands

The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.

C-Suite Speaks Leadership

Scant Pipeline Competition For Roche’s Novel Flu Antiviral

With Priority Review given to Roche’s novel flu antiviral baloxavir marboxil for potential approval in the US, and Shionogi’s launch of the product under the brand name Xofluza, it looks set to lead the market for single-dose antivirals.

Review Pathway Infectious Diseases

Kala Hopes To Stride Into Dry Eye Market This Year

Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.

Ophthalmic Commercial

Externally Developed Products Mean Bigger Revenues, But Not In Diabetes

External innovation directly links to commercial success for big pharma, and will continue to do so until 2026, according to a new report by Datamonitor Healthcare.

Growth Commercial
See All
UsernamePublicRestriction

Register